Spinal Muscular Atrophy Treatment Market Size

  • Report ID: 2724
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Spinal Muscular Atrophy Treatment Market Size

Spinal Muscular Atrophy Treatment Market size was over USD 5.9 billion in 2024 and is anticipated to cross USD 53.02 billion by 2037, witnessing more than 18.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of spinal muscular atrophy treatment is estimated at USD 6.82 billion.

According to the National Library of Medicine, in October 2023, the incidence of SMA is estimated at 1 in 6000–10,000, with a carrier frequency of 1/40–1/60. Even though spinal muscular atrophy is considered a rare disease, the rising incidence of the cases, especially among newborn children is anticipated to boost the spinal muscular atrophy treatment market during the forecast period.

The growing prevalence of the genetic disorder has led to a rising awareness and demand for early diagnosis. Advances in gene therapies, and increasing investments in R&D, particularly in RNA-based therapies, have propelled the demand for novel, effective treatments. Governments and healthcare organizations are also playing a crucial role by providing incentives and fast-tracking drug approvals for rare diseases. Personalized medicine approaches, aim to improve patient outcomes by tailoring treatments to specific genetic profiles. Collaborations between biotech firms and academic institutions are further accelerating drug discovery, while patient advocacy groups are raising awareness and driving demand for innovative therapies in the spinal muscular atrophy treatment market.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2724
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of spinal muscular atrophy treatment is estimated at USD 6.82 billion.

Spinal Muscular Atrophy Treatment Market size was over USD 5.9 billion in 2024 and is anticipated to cross USD 53.02 billion by 2037, witnessing more than 18.4% CAGR during the forecast period i.e., between 2025-2037.

North America industry is set to dominate majority revenue share by 2037, due to high healthcare expenditure, amplified cases of SMA patients in the region, high awareness among the populace regarding the disease, and several active organizations and campaigns working tirelessly to raise awareness and contributes to the society.

The major players in the market are PTC Therapeutics, Voyager Therapeutics, Inc, Astellas Pharma Inc., Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd, CYTOKINETICS, INC., Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc, and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample